Compared to their respective control cells, CD133 OE CRC cells displayed significant resistance to chemotherapeutic agents (DOX, MMC, VCR and CTX) (Fig. 3a) and markedly inhibited DOX uptake (Fig. 3b, c). The gene discussed is PROM1; the disease is colorectal carcinoma.